About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output a ...

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Moderna and Merck are presenting the data at the American Society of Clinical Oncology annual meeting in Chicago. The shot is a key part of Moderna's pipel ...

The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (MRNA -5.90%). Biotech stocks generally rise after a product they spent years developing earns marketing approval, but this isn't what happened. Why Moderna stock fell Moderna's bizarre stock price performance during the week ending May 31 had two main factors. First, enthusiasm for the vaccine dev ...

This news could be worth billions... Moderna (MRNA -5.90%) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in billions of dollars in earnings. But in later pandemic days, investors started worrying about Moderna's dependence on its only commercialized product, and that has weighed on the stock price. Shares of the biotech company have dropped 70% from their high back in 2021. Moderna m ...

Summary of Moderna, Inc. (NASDAQ:MRNA) Conference Call Company Overview - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Event**: Bernstein's 40th Annual Strategic Decisions Conference - **Date**: May 31, 2024 - **Participants**: - Stephane Bancel - CEO - Courtney Breen - Bernstein U.S. biopharma analyst Key Points Industry and Company Insights - **mRNA Technology**: Moderna's foundation is based on mRNA as a digital medicine, allowing for the creation of drugs that are not feasible with traditional methods [3][4] - **Platform Company**: Moderna aims to be a platform company with a focus on scalability and efficiency in drug development, leveraging synthetic manufacturing processes [9][10] - **Pipeline**: The company has a robust pipeline with 28 vaccines and 16 therapeutic programs, targeting a total addressable market (TAM) of approximately $27 billion for respiratory vaccines and over $10 billion for rare diseases [11][12] Financial and Market Position - **Investment in R&D**: Moderna's R&D investment is comparable to that of established companies like Amgen, indicating a strong commitment to innovation [11] - **Market Leadership**: The company anticipates becoming the largest vaccine company globally, with a significant number of products in late-stage development [14][15] Product Development and Approvals - **Upcoming Approvals**: Expected approvals include RSV vaccine and flu plus COVID combination vaccine, with potential market availability as early as fall 2025 [16][15] - **Cancer Treatment**: Moderna is optimistic about its cancer treatment pipeline, particularly in enhancing the efficacy of existing therapies like KEYTRUDA [20][21] Manufacturing and Scalability - **Manufacturing Efficiency**: The company is focused on reducing manufacturing cycle times and increasing throughput, which is critical for individualized treatments [24][25] - **New Facilities**: Moderna is building new manufacturing plants to support its growing pipeline and improve production capabilities [63] Commercial Strategy - **Leadership Role**: Stephane Bancel has taken on the role of Chief Commercial Officer to ensure the commercial success of Moderna's products [29][30] - **Customer Engagement**: The company is enhancing its relationships with pharmacies and healthcare providers to streamline distribution and improve customer intimacy [41][42] Regulatory and Safety Considerations - **FDA Interactions**: Moderna is in the process of obtaining FDA approvals for its products, with a focus on safety and efficacy data [45][46] - **Safety Profile**: The company believes it may have a safety advantage over competitors, particularly concerning rare side effects like Guillain-Barré syndrome [49][50] Future Outlook - **Long-term Vision**: Over the next decade, Moderna aims to expand its vaccine offerings significantly, addressing a wide range of diseases, including cancers linked to viral infections [18][19] - **mRNA Platform Evolution**: The company is exploring the potential of its mRNA platform to revolutionize vaccine development and stockpiling strategies in response to emerging infectious diseases [51][52] Additional Considerations - **Collaboration Opportunities**: Moderna is in discussions with the U.S. government regarding potential collaborations for vaccine development, particularly for avian flu [57][58] - **Market Dynamics**: The company is adapting its strategies based on lessons learned from the COVID-19 pandemic, particularly in manufacturing and rapid response capabilities [56][59] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Moderna's innovative approach and future ambitions in the biopharmaceutical industry.

Moderna's sell-off this week is for the birds. Shares of Moderna (MRNA 2.41%) were sinking 9% lower this week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The decline appears to be the result of investors taking profits after Moderna stock soared 25% last week. What's behind the big moves for Moderna? Avian flu. Reports of human cases of H5N1 avian flu (also known as bird flu) in Australia and the U.S. caused several vaccine stocks to jump last week. The sell- ...

Forbes Community Guidelines Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space. In order to do so, please follow the posting rules in our site's Terms of Service. We've summarized some of those key rules below. Simply put, keep it civil. Your post will be rejected if we notice that it seems to contain: User accounts will be blocked if we notice or believe that users are engaged in: So, how ...

Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero. Between juggling FDA approvals, new product pipelines and regulatory changes, it takes a lot of due diligence to stay on top of which biotech stocks to buy. Some investors even go so far as to look into the more specific clinical phase trials and even learn about the specific medical technology behind each treatment. Over the past few months, biotech stocks have bee ...

Despite the declining top line, shares of Moderna (MRNA) continue to soar thanks to its encouraging pipeline updates and potential product launches over the next few years. The company boasts of a pipeline of more than 40 mRNA-based investigational candidates across different stages of development, targeting multiple indications, including cancer and cardiovascular. Being one of the handful of makers of a COVID-19 vaccine, Moderna reaped the benefits of the COVID-19 pandemic, allowing it to strengthen its c ...

It's not uncommon for companies to face regulatory setbacks -- and It's not the end of the world. Biotech investors aren't fond of regulatory delays. Brand-new products have a limited shelf life before they run out of patent protection. The less time they spend on the market, the less they will generate in sales. But in this The past two-and-a-half years have been rough for Moderna (MRNA 1.58%). Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche t ...